Gilead

Hep-C Treatment On a Budget - Why Prices are Plummeting

After months of waiting and anticipation, the hepatitis C treatment price wars are finally getting under way. Express Scripts, the largest pharmacy benefits manager in the U.S., has released a new treatment from AbbVie as its exclusive treatment for patients with genotype 1, the most common form of the chronic disease. This drug covers 75% of the estimated 3.2 million Americans who are infected. And this new drug will likely change the market for the hepatitis C treatments that are currently led by a pair of medications from Gilead Sciences which is likely to reach $20 billion in revenue next year thanks to demand for its treatments.

Recommended Stories

Real Time Analytics